Retatrutide UK: The Triple Hormone Weight Loss Injection Explained (GLP-1 + GIP + Glucagon)
Get our latest weight-loss and health guides straight to your inbox.
Rahul Puri, pharmacist — explaining peptide evidence, safety and UK regulation.
Evidence update: 7 October 2026.
Retatrutide is an investigational peptide that targets three hormone receptors. Its human trial results deserve serious attention, but promising research and an available, authorised treatment are different stages.
Is retatrutide available in the UK?
Retatrutide is not a licensed UK treatment. In its 24 July 2026 warning, the MHRA specifically stated that retatrutide had not been authorised for UK use and warned against products sold online. Lilly continued to describe it as investigational in its 29 September 2026 update.
Puri Pharmacy does not sell, supply or prescribe retatrutide. An online label cannot establish that a product contains the trial medicine, in the stated quantity or at an appropriate quality. This article is an explanation of the evidence, not an access or waiting-list offer.
What is retatrutide?
Retatrutide (also known as LY3437943) is an investigational medicine being studied for obesity and metabolic disease. It’s designed to activate three receptors involved in weight regulation:
-
GLP-1 (glucagon-like peptide-1)
-
GIP (glucose-dependent insulinotropic polypeptide)
-
Glucagon
This “triple agonist” design is why retatrutide is often described as a triple-hormone weight loss injection.
Is retatrutide a peptide? What is a peptide?
Yes, retatrutide is a synthetic peptide medicine. In simple terms:
-
A peptide is a short chain of amino acids (the same building blocks that make proteins).
-
Many hormones in the body are peptide based signals, which is why peptide medicines are common in metabolic health.
Why are peptide medicines usually injections?
Many peptide medicines are injected because digestion and poor absorption can limit oral delivery. Some have oral formulations; the route depends on the specific medicine and preparation. An injectable route does not itself establish effectiveness or safety.
Does “peptide” mean “safe”?
Not automatically. “Peptide” describes the type of molecule, not the quality of what you’re being sold. The MHRA has repeatedly warned about fake or unlicensed pens being sold via unregulated routes which can mean the contents, dose, sterility and storage can’t be trusted.
Retatrutide trial results: the 2026 evidence
The following figures are trial-group averages, not a prediction for an individual. The milligram amounts identify study groups; they are not instructions for self-use.
TRIUMPH-1: adults without diabetes
Lilly’s May 2026 Phase 3 topline report described 2,339 participants with obesity, or overweight with a weight-related condition, without diabetes. At 80 weeks, the 12 mg group had an average 28.3% weight reduction versus 2.2% with placebo under the efficacy estimand, which estimates effects assuming continued treatment without prohibited weight-management treatments.
The treatment-regimen analysis, which includes the effects of discontinuation and other weight-management treatment, gave 25.0% versus 3.9%. That difference is useful context for the headline number. Discontinuation because of adverse events was 11.3% at 12 mg versus 4.9% with placebo. This source is a manufacturer’s topline report, so its status should stay visible.
TRIUMPH-2: adults with type 2 diabetes
In its 29 September 2026 detailed results release, Lilly reported on 1,152 participants with type 2 diabetes and obesity or overweight. At 80 weeks, the 12 mg group lost an average 20.8% of body weight versus 4.0% with placebo, using the efficacy estimand. HbA1c fell by 1.5 percentage points at 12 mg versus 0.2 with placebo.
Lilly states that the results were presented at EASD and published in The Lancet. The figures here are taken from its linked release. Adverse-event discontinuations were 7.7% at 12 mg versus 4.9% with placebo. These findings concern a different population from TRIUMPH-1; the two percentages should not be read as a direct comparison of treatment performance.
What the results do and do not establish
These are substantial average weight changes in controlled human research. It is reasonable to describe retatrutide as promising. It is not reasonable to turn an average into a guarantee, or to transfer results from a trial product to a vial bought online.
A useful appraisal asks about the population, comparison group, time point, missing data and analysis method. It also asks whether the outcomes that matter to a patient improved. Weight reduction, changes in risk markers and fewer heart attacks are different outcomes; one should not be presented as proof of another.
Is retatrutide better than Wegovy or Mounjaro?
A list of headline percentages from separate trials cannot establish that. Differences in participants, diabetes status, follow-up, treatment adherence and statistical methods can change the result. A reliable comparison needs evidence designed to answer that question. Targeting three receptors is a mechanism, not by itself proof of superiority.
Retatrutide side effects and unresolved safety questions
Both linked Phase 3 reports describe gastrointestinal adverse events. TRIUMPH-1 also reported altered skin sensation (dysesthesia), including 12.5% at 12 mg versus 0.9% with placebo. The numbers who stop treatment because of adverse events belong alongside the benefits, even when many individual events are described as mild or moderate.
Trial safety data cannot certify every person, every duration of use or every product sold under the same name. A normal blood test also cannot establish product identity, sterility or an acceptable benefit–risk balance. See our explanations of peptide risks and the limits of blood testing.
Evidence summary
- What human evidence shows: the Phase 3 reports above show substantial average weight reduction in the populations studied, with glycaemic improvements reported in the diabetes trial.
- What is not established: these results do not establish suitability for an individual, superiority from cross-trial percentages, or the quality of online products.
- Main safety uncertainties: tolerability, less common and longer-term harms, and applicability beyond trial populations remain relevant to assessment.
- What would change the assessment: further transparent clinical results, longer follow-up and a formal UK regulatory decision for a defined product and indication.
When could retatrutide become available in the UK?
A confirmed UK launch date cannot be inferred from a trial readout. In September, Lilly said it planned a US regulatory submission in the first quarter of 2027. That is a company plan, not an approval or a UK availability date. UK authorisation and any NHS access decision are separate questions.
Continue reading Rahul’s peptide analysis
- Start with the UK guide to peptide science, evidence and safety.
- Read how to assess a peptide study and what UK medicine authorisation means.
- Subscribe to Puri’s health updates, including peptide analysis.
Follow Rahul’s peptide analysis
Subscribe to Puri Pharmacy’s health updates, including Rahul Puri’s explanations of peptide evidence, safety and UK regulation. This is an educational newsletter, not access to peptide treatment.
By subscribing, you agree to receive Puri Pharmacy’s health emails. Read our privacy policy.
To suggest a research claim for explanation, use the Puri Pharmacy contact form and include its source. For individual symptoms or treatment decisions, seek appropriate clinical advice. Do not wait for a routine reply if you need urgent care.
